Close Menu
Home › Natera Q2 Revenues Climb 21 Percent

Natera Q2 Revenues Climb 21 Percent

Aug 08, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Natera reported after the close of the market on Wednesday that its second quarter 2018 revenues rose 21 percent year over year.

The San Carlos, California-based molecular diagnostics firm reported total Q2 2018 revenues of $63.1 million, compared to $52.3 million in Q2 2017, beating analysts' average estimate of $61.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Molecular Diagnostics

  1. Roche Gains FDA Clearance for Cobas Babesia Blood Test

  2. Germany's Publicly Funded Insurance to Cover NIPT Under Limited Circumstances

  3. HTG Molecular Diagnostics Prices $20M in Stock Offerings

  4. Inex Innovate to Launch New Molecular Tests for Ovarian Cancer, Breast Cancer in Asia

    Premium

  5. Bionano Genomics Commences Public Stock Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.